➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Johnson and Johnson
AstraZeneca
Medtronic
Colorcon

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,526,764

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,526,764
Title:Combination of an insulin and a GLP-1-agonist
Abstract: The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Inventor(s): Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:13/123,835
Patent Claims: 1. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 20 .mu.g/ml to about 150 .mu.g/ml.

2. The pharmaceutical formulation of claim 1, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 25, 33, 40, 66, or 75 .mu.g/mL.

3. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 25 .mu.g/mL.

4. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 33 .mu.g/mL.

5. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 40 .mu.g/mL.

6. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 66 .mu.g/mL.

7. The pharmaceutical formulation of claim 2, wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 75 .mu.g/mL.

8. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) AVE0010 or a pharmaceutically acceptable salt thereof; wherein the concentration of insulin glargine is about 100 units/mL, and wherein insulin glargine and AVE0010 are present in a ratio of about 1.5 units to about 4 units of insulin glargine to 1 .mu.g of AVE0010.

9. The pharmaceutical formulation of claim 8, wherein insulin glargine and AVE0010 are present in a ratio of about 3 units of insulin glargine to 1 .mu.g of AVE0010.

10. The pharmaceutical formulation of claim 8, wherein insulin glargine and AVE0010 are present in a ratio of about 2 units of insulin glargine to 1 .mu.g of AVE0010.

11. A pharmaceutical formulation comprising a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the dosage of insulin glargine is between about 5 units and about 100 units, and the dosage of AVE0010 is between about 5 .mu.g and about 2 mg.

12. The pharmaceutical formulation of claim 11, wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 10 .mu.g and about 30 .mu.g.

13. The pharmaceutical formulation of claim 11, wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 10 .mu.g and about 20 .mu.g.

14. The pharmaceutical formulation of claim 1, 8, or 11, wherein the pharmaceutical formulation is a liquid formulation suitable for parenteral administration.

15. The pharmaceutical formulation of claim 1, 8, or 11, wherein the pharmaceutical formulation is suitable for administration once daily.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.